$293 Million is the total value of Aquilo Capital Management, LLC's 13 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 21.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | New | SPDR S&P BIOTECH ETF TRput | $55,703,000 | – | 750,000 | +100.0% | 19.01% | – |
| ARWR | Buy | ARROWHEAD PHARMACEUTICALS IN | $42,200,000 | -12.4% | 1,198,515 | +14.4% | 14.40% | +103.4% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $36,192,000 | -27.5% | 716,539 | -8.3% | 12.35% | +68.3% |
| MRUS | Buy | MERUS N V | $33,442,000 | +0.3% | 1,477,109 | +17.1% | 11.41% | +132.8% |
| ARVN | Buy | ARVINAS INC | $32,483,000 | -30.6% | 771,745 | +11.0% | 11.08% | +61.2% |
| RGNX | Buy | REGENXBIO INC | $28,842,000 | -22.3% | 1,167,684 | +4.4% | 9.84% | +80.4% |
| QURE | Buy | UNIQURE NV | $18,109,000 | +11.2% | 971,490 | +7.8% | 6.18% | +158.1% |
| AMYT | Buy | AMRYT PHARMA PLCsponsored ads | $13,048,000 | -3.8% | 1,866,652 | +13.8% | 4.45% | +123.4% |
| ARGX | ARGENX SEsponsored adr | $9,093,000 | +20.2% | 24,000 | 0.0% | 3.10% | +179.0% | |
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $6,987,000 | -37.8% | 3,736,280 | +0.7% | 2.38% | +44.3% |
| GMAB | Buy | GENMAB A/Ssponsored ads | $6,980,000 | +15.2% | 214,848 | +28.3% | 2.38% | +167.3% |
| FDMT | Sell | 4D MOLECULAR THERAPEUTICS IN | $6,014,000 | -77.3% | 861,607 | -50.9% | 2.05% | -47.4% |
| SPRO | Buy | SPERO THERAPEUTICS INC | $3,943,000 | -91.4% | 5,321,231 | +0.8% | 1.35% | -80.1% |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -350,000 | -100.0% | -23.23% | – |
| XBI | Exit | SPDR S&P BIOTECH ETF TRcall | $0 | – | -2,000,000 | -100.0% | -26.42% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PIERIS PHARMACEUTICALS INC | 20 | Q3 2023 | 7.1% |
| ARROWHEAD PHARMACEUTICALS INC | 18 | Q3 2023 | 22.1% |
| UNIQURE NV | 18 | Q1 2023 | 10.8% |
| SPERO THERAPEUTICS INC | 16 | Q3 2022 | 15.8% |
| REGENXBIO INC | 16 | Q3 2023 | 12.6% |
| BLUEPRINT MEDICINES CORP | 15 | Q3 2023 | 17.3% |
| ARGENX SE | 15 | Q3 2023 | 3.7% |
| SPDR S&P BIOTECH ETF TR | 14 | Q4 2022 | 52.1% |
| MERUS N V | 14 | Q3 2023 | 13.0% |
| GENMAB A/S | 13 | Q3 2023 | 3.9% |
View Aquilo Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Spero Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Merus N.V. | February 14, 2020 | 814,505 | 2.8% |
| SYNLOGIC, INC.Sold out | February 14, 2020 | 0 | 0.0% |
View Aquilo Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-03-18 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
View Aquilo Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.